ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pulmonary"

  • Abstract Number: 0912 • ACR Convergence 2020

    Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension

    Takanori Ito1, Takehiro Nakai2, Genki Kidoguchi2, Sho Fukui2, Hiroki Ozawa2, Satoshi Kawaai2, Yukihiko Ikeda2, Hisanori Shimizu2, Yasuhiro Suyama3, Atsushi Nomura2, Hiromichi Tamaki1, Kenichi Yamaguchi2 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 3JR Tokyo General Hospital, Tokyo, Japan

    Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…
  • Abstract Number: 1957 • ACR Convergence 2020

    A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland

    Ilya Korsunsky1, Kevin Wei2, Mathilde Pohin3, Edy Kim4, Jason Turner5, Saba Nayar6, Benjamin Fisher7, Karim Raza8, Matthias Friedrich9, Jennifer Marshall5, Adam Croft5, Mark Coles10, Andreas Frei11, Andrew Filer12, Francesca Barone5, Kara Lassen11, Fiona Powrie10, Christopher Buckley13, Michael Brenner2 and Soumya Raychaudhuri14, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Oxford, United Kingdom, 4Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 5Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, 6Institute for Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 7University Hospitals Birmingham NHS Foundation Trust-Birmingham, Birmingham, United Kingdom, 8Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 9Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 10Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 11Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland, 12Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 13University of Birmingham, Birmingham, United Kingdom, 14Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Pro-inflammatory fibroblasts have been independently implicated in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), interstitial lung disease (ILD), and Sjogren’s syndrome…
  • Abstract Number: 0925 • ACR Convergence 2020

    Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension

    Alexandra Boucher1, Yongseok Park2, Shannon Zalewski3, Maureen Laffoon2, Thomas Medsger4, Robert Lafyatis2 and Robyn Domsic5, 1University of Pittsburgh, Camp Hill, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Washington University Barnes Jewish Hospital, Saint Louis, MO, 4University of Pittsburgh School of Medicine, Verona, PA, 5University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
  • Abstract Number: 1038 • ACR Convergence 2020

    STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis

    Marcia Friedman1, Brian Le2, Dongseok Choi2 and James Rosenbaum2, 1Oregon Health and Science University, Portland, OR, 2Oregon Health & Science University, Portland, OR

    Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
  • Abstract Number: 1039 • ACR Convergence 2020

    Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis

    Marcia Friedman1, Stevens Janelle2, Julianna Desmarais3, Daniel Seifer3, Brian Le3, Kimberly Ogle3, Christina Harrington3, Peter Jackson4, Dongseok Choi3 and James Rosenbaum3, 1Oregon Health and Science University, Portland, OR, 2Tuality Healthcare, Hillsboro, OR, 3Oregon Health & Science University, Portland, OR, 4Johns Hopkins University, Baltimore, MD

    Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
  • Abstract Number: 1040 • ACR Convergence 2020

    Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand

    Athiwat Tripipitsiriwat1, Chulaluk Komoltri1, Ruchira Ruangchira-Urai1 and Patompong Ungprasert2, 1Mahidol University, Bangkok, Thailand, 2Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH

    Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…
  • Abstract Number: 1051 • ACR Convergence 2020

    Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers

    Kristin D'Silva1, Iazsmin Bauer Ventura2, Marcy Bolster3, Flavia Castelino4, Amita Sharma1, Brent Little1, Ayodeji Adegunsoye2, Mary Strek2, Sydney Montesi1 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2University of Chicago, Chicago, IL, 3Massachusetts General Hospital, Concord, MA, 4Massachusetts General Hospital/Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with…
  • Abstract Number: 0015 • ACR Convergence 2020

    COVID -19 Lung Inflammation – What Have We Learnt so Far ?

    Sriya Gokaraju1, Maria Darda2, Vinod Vijayaraghavan Nalini Warrier3, Irina Duta3, Fiona Hayes3, Yasser Ahmed4 and Gouri Koduri3, 1Southend University Hospital NHS Trust, Essex, United Kingdom, 2Southend University Hospital NHS Trust, Essex, United Kingdom, 3Southend University Hospital NHS Trust, Essex, United Kingdom, 4Southend University Hospital, Essex, United Kingdom

    Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
  • Abstract Number: 1052 • ACR Convergence 2020

    Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

    Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
  • Abstract Number: 0279 • ACR Convergence 2020

    Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus

    Naci Senkal1, Esen Kiyan2, Elif Kocasoy-Orhan3, Ali Demir4, Mehmet Aydogan5, Yasemin Yalcinkaya6, Ahmet Gul6, Murat Inanc7, Mahdume Lale Öcal6 and Bahar Artım-Esen6, 1Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 2Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 3Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 4Fulya Radiologic Imaging Center, İstanbul, Turkey, 5Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 6Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 7Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
  • Abstract Number: 1200 • ACR Convergence 2020

    Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function

    Tim Wilson1, Joshua Solomon2, Jeffrey Swigris2, Erika Darrah3 and M Kristen Demoruelle1, 1University of Colorado, Denver, CO, 2National Jewish Health, Denver, CO, 3Division of Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) associated-interstitial lung disease (ILD) affects approximately 10% of RA patients. It is a leading cause of morbidity and mortality, which is…
  • Abstract Number: 0383 • ACR Convergence 2020

    Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials

    Elizabeth Volkmann1, Ning Li2, Michael Roth2, Carol Feghali-Bostwick3, Richard Silver4, DeAnna Baker Frost5, Shervin Assassi6, Grace Kim2, Jonathan Goldin2 and Donald Tashkin2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, 3The Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, 5The Medical University of South Carolina, Charleston, 6University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
  • Abstract Number: 1244 • ACR Convergence 2020

    Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease

    Joanna Marco1, Gregory Gardner1 and Nishant Gupta2, 1University of Washington, Seattle, WA, 2University of Cincinnati, Cincinnati

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
  • Abstract Number: 0387 • ACR Convergence 2020

    Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension

    Alper Sari1, Christopher Denton2, Svetlana Nihtyanova3, Benjamin Schreiber4 and Voon Ong3, 1Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, 2University College London, London, United Kingdom, 3Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, 4UCL, London, United Kingdom

    Background/Purpose: Iron deficiency (ID) is more frequent in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) than those without and associated with worse prognosis. There…
  • Abstract Number: 1378 • ACR Convergence 2020

    Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

    Shervin Assassi1, Nan Shao2, Ziwei Yin2, Elizabeth Volkmann3, Donald Zoz2 and Thomas Leonard2, 1University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, 3University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of SSc. SSc-ILD is usually detected in a patient known to have SSc, but ILD may…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology